Of these, 1,956 gastrointestinal reports were for exenatide (9.19%), 2,891 for liraglutide (13.58%), 10,757 for dulaglutide (50.55%), 182 for lixisenatide (0.86%), and 5,567 (26.16%) for semaglutide ( Figure 1 )
We are overwriting a signal the body is already sending, and were doing it at scale, in millions of people, without a baseline measurement to tell us what were overwriting
At week 48, 72% of participants with prediabetes at baseline had reverted to normoglycemia, compared to 22% in the placebo group [2]
Its essential for patients to follow the specific dosing and administration instructions provided by their healthcare provider to ensure the safe and effective use of GLP-1 agonists